Patents by Inventor Stanislas Mayer
Stanislas Mayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066027Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of pain, an autoimmune disorder, an autoinflammatory disorder, an inflammatory disorder, a central nervous system disorder, spinal cord injury, a metabolic disorder, a gastrointestinal disorder, a cardiovascular disorder, a fibrotic disorder, a respiratory disorder, a skin disorder, an allergic disorder, or cancer.Type: ApplicationFiled: December 3, 2021Publication date: February 29, 2024Inventors: Stanislas MAYER, Anne-Laure BLAYO, Mickaël FER, Anaïs BARRÉ, Mathieu MICHAUT, Gaël HOMMET, Stephan SCHANN, Baptiste RUGERI
-
Publication number: 20240018125Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.Type: ApplicationFiled: September 28, 2021Publication date: January 18, 2024Inventors: Jean-Philippe HERBEUVAL, Anaïs BARRÉ, Julie CASSOU, Stanislas MAYER, Patrick BAZZINI
-
Publication number: 20220378772Abstract: The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.Type: ApplicationFiled: October 2, 2020Publication date: December 1, 2022Applicant: Domain TherapeuticsInventors: Anne-Laure BLAYO, Ismet DORANGE, Gaël HOMMET, Baptiste MANTEAU, Stanislas MAYER, Stephan SCHANN
-
Patent number: 11472806Abstract: The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: GrantFiled: May 14, 2018Date of Patent: October 18, 2022Assignee: Domain TherapeuticsInventors: Anne-Laure Blayo, Thomas Catelain, Ismet Dorange, Cédric Genet, Baptiste Manteau, Stanislas Mayer, Stephan Schann
-
Publication number: 20220298135Abstract: The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction.Type: ApplicationFiled: August 6, 2020Publication date: September 22, 2022Applicant: Domain TherapeuticsInventors: Stephan SCHANN, Mickaël FER, Stanislas MAYER, Christelle DOEBELIN
-
Publication number: 20220144853Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.Type: ApplicationFiled: March 27, 2020Publication date: May 12, 2022Applicants: Université de Paris, Centre National de la Recherche ScientifiqueInventors: Nassima BEKADDOUR BENATIA, Mathieu RODERO, Jean-Philippe HERBEUVAL, Nicolas PIETRANCOSTA, Nikaïa SMITH, Anaïs BARRÉ, Julie CASSOU, Stanislas MAYER
-
Publication number: 20220089609Abstract: The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.Type: ApplicationFiled: July 26, 2019Publication date: March 24, 2022Applicant: DOMAIN THERAPEUTICSInventors: Camille AMALRIC, Anaïs BARRE, Stephan SCHANN, Stanislas MAYER, Ismet DORANGE, Baptiste MANTEAU, Anne-Laure BLAYO
-
Publication number: 20210380606Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.Type: ApplicationFiled: October 22, 2019Publication date: December 9, 2021Applicant: Merck Patent GmbHInventors: Anne-Laure BLAYO, Baptiste MANTEAU, Ismet DORANGE, Stanislas MAYER, Stephan SCHANN, Thomas CATELAIN
-
Publication number: 20210361669Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.Type: ApplicationFiled: October 22, 2019Publication date: November 25, 2021Applicant: MERCK PATENT GMBHInventors: Anne-Laure BLAYO, Bapriste MANTEAU, Camille AMALRIC, Stanislas MAYER, Stehan SCHANN, Mickaël FER
-
Patent number: 11008323Abstract: The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The tricyclic 1,4-benzodiazepinone derivatives of formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: GrantFiled: November 11, 2016Date of Patent: May 18, 2021Assignee: Domain TherapeuticsInventors: Stephan Schann, Stanislas Mayer, Baptiste Manteau
-
Publication number: 20200140438Abstract: The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: ApplicationFiled: May 14, 2018Publication date: May 7, 2020Inventors: Anne-Laure BLAYO, Thomas CATELAIN, Ismet DORANGE, Cédric GENET, Baptiste MANTEAU, Stanislas MAYER, Stephan SCHANN
-
Publication number: 20190152979Abstract: Pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them are disclosed. The compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signaling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signaling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Applicant: DOMAIN THERAPEUTICSInventors: Stephan SCHANN, Stanislas MAYER, Baptiste MANTEAU
-
Patent number: 10221179Abstract: The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: GrantFiled: September 25, 2015Date of Patent: March 5, 2019Assignee: DOMAIN THERAPEUTICSInventors: Stephan Schann, Stanislas Mayer, Baptiste Manteau
-
Publication number: 20180346468Abstract: The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The tricyclic 1,4-benzodiazepinone derivatives of formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: ApplicationFiled: November 11, 2016Publication date: December 6, 2018Inventors: Stephan SCHANN, Stanislas MAYER, Baptiste MANTEAU
-
Publication number: 20170305913Abstract: The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: ApplicationFiled: September 25, 2015Publication date: October 26, 2017Applicant: DOMAIN THERAPEUTICSInventors: Stephan SCHANN, Stanislas MAYER, Baptiste MANTEAU
-
Patent number: 9434734Abstract: The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: GrantFiled: May 21, 2013Date of Patent: September 6, 2016Assignee: DOMAIN THERAPEUTICSInventors: Stanislas Mayer, Stephan Schann
-
Patent number: 9029393Abstract: The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors could be beneficial.Type: GrantFiled: January 25, 2010Date of Patent: May 12, 2015Assignee: Kaldi Pharma, SASInventors: Stephan Schann, Stanislas Mayer
-
Publication number: 20150105381Abstract: The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.Type: ApplicationFiled: May 21, 2013Publication date: April 16, 2015Inventors: Stanislas Mayer, Stephan Schann
-
Patent number: 8962627Abstract: The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.Type: GrantFiled: October 29, 2010Date of Patent: February 24, 2015Assignee: Prestwick Chemical, Inc.Inventors: Stephan Schann, Stanislas Mayer, Christophe Morice, Bruno Giethlen
-
Publication number: 20120277212Abstract: The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.Type: ApplicationFiled: October 29, 2010Publication date: November 1, 2012Applicants: PRESTWICK CHEMICAL, INC., DOMAIN THERAPEUTICSInventors: Stephan Schann, Stanislas Mayer, Christophe Morice, Bruno Giethlen